Mélika Ben Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mélika Ben Ahmed has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Maha Abdeladhim
Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
8 shared publicationsHechmi Louzir
Laboratory of Transmission, Control and Immunobiology of Infection, LR11IPT02, Institut Pasteur de Tunis, Tunis, Tunisia
6 shared publicationsNadia Belhadj Hmida
Department of Clinical Immunology, Institut Pasteur de Tunis, Tunis, Tunisia
4 shared publicationsSoumaya Marzouki
Laboratory of Transmission, Control and Immunobiology of Infections, LR11IPT02, Institut Pasteur de Tunis, 1002 Tunis, Tunisia
4 shared publicationsAfif Ben Salah
Laboratory of Transmission, Control and Immunobiology of Infection, LR11IPT02, Institut Pasteur de Tunis, Tunis, Tunisia
3 shared publications- Ahlem Ben Hmid
Laboratory of Clinical Immunology, Institut Pasteur de Tunis, Tunis, Tunisia
2 shared publications
Latest Publications
- Open Access
- 3 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0174835
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma
Sustained activation of JAK/STAT3 signaling pathway is classically described in Multiple Myeloma (MM). One explanation could be the silencing of the JAK/STAT suppressor genes, through the hypermethylation of SHP-1 and SOCS-1, previously demonstrated in MM cell lines or in whole bone marrow aspirates. The link between such suppressor gene silencing and the degree of bone marrow invasion or the treatment response has not been evaluated in depth. Using real-time RT-PCR, we studied the expression profile of three JAK/STAT suppressor genes: SHP-1, SHP-2 and SOCS-1 in plasma cells freshly isolated from the bone marrows of MM patients and healthy controls. Our data demonstrated an abnormal repression of such genes in malignant plasma cells and revealed a significant correlation between such defects and the sustained activation of the JAK/STAT3 pathway during MM. The repressed expression of SHP-1 and SHP-2 correlated significantly with a high initial degree of bone marrow infiltration but was, unexpectedly, associated with a better response to the induction therapy. Collectively, our data provide new evidences that substantiate the contribution of JAK/STAT suppressor genes in the pathogenesis of MM. They also highlight the possibility that the decreased gene expression of SHP-1 and SHP-2 could be of interest as a new predictive factor of a favorable treatment response, and suggest new potential mechanisms of action of the therapeutic molecules. Whether such defect helps the progression of the disease from monoclonal gammopathy of unknown significance to MM remains, however, to be determined.
- 3 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0174835
Open AccessAbnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma
Sustained activation of JAK/STAT3 signaling pathway is classically described in Multiple Myeloma (MM). One explanation could be the silencing of the JAK/STAT suppressor genes, through the hypermethylation of SHP-1 and SOCS-1, previously demonstrated in MM cell lines or in whole bone marrow aspirates. The link between such suppressor gene silencing and the degree of bone marrow invasion or the treatment response has not been evaluated in depth. Using real-time RT-PCR, we studied the expression profile of three JAK/STAT suppressor genes: SHP-1, SHP-2 and SOCS-1 in plasma cells freshly isolated from the bone marrows of MM patients and healthy controls. Our data demonstrated an abnormal repression of such genes in malignant plasma cells and revealed a significant correlation between such defects and the sustained activation of the JAK/STAT3 pathway during MM. The repressed expression of SHP-1 and SHP-2 correlated significantly with a high initial degree of bone marrow infiltration but was, unexpectedly, associated with a better response to the induction therapy. Collectively, our data provide new evidences that substantiate the contribution of JAK/STAT suppressor genes in the pathogenesis of MM. They also highlight the possibility that the decreased gene expression of SHP-1 and SHP-2 could be of interest as a new predictive factor of a favorable treatment response, and suggest new potential mechanisms of action of the therapeutic molecules. Whether such defect helps the progression of the disease from monoclonal gammopathy of unknown significance to MM remains, however, to be determined.
- Open Access
- 14 September 2015
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 9 (9) , e0003991
Validation of Recombinant Salivary Protein PpSP32 as a Suitable Marker of Human Exposure to Phlebotomus papatasi, the Vector of Leishmania major in Tunisia
During a blood meal, female sand flies, vectors of Leishmania parasites, inject saliva into the host skin. Sand fly saliva is composed of a large variety of components that exert different pharmacological activities facilitating the acquisition of blood by the insect. Importantly, proteins present in saliva are able to elicit the production of specific anti-saliva antibodies, which can be used as markers for exposure to vector bites. Serological tests using total sand fly salivary gland extracts are challenging due to the difficulty of obtaining reproducible salivary gland preparations. Previously, we demonstrated that PpSP32 is the immunodominant salivary antigen in humans exposed to Phlebotomus papatasi bites and established that humans exposed to P. perniciosus bites do not recognize it. Herein, we have validated, in a large cohort of 522 individuals, the use of the Phlebotomus papatasi recombinant salivary protein PpSP32 (rPpSP32) as an alternative method for testing exposure to the bite of this sand fly. We also demonstrated that screening for total anti-rPpSP32 IgG antibodies is sufficient, being comparable in efficacy to the screening for IgG2, IgG4 and IgE antibodies against rPpSP32. Additionally, sera obtained from dogs immunized with saliva of P. perniciosus, a sympatric and widely distributed sand fly in Tunisia, did not recognize rPpSP32 demonstrating its suitability as a marker of exposure to P. papatasi saliva. Our data indicate that rPpSP32 constitutes a useful epidemiological tool to monitor the spatial distribution of P. papatasi in a particular region, to direct control measures against zoonotic cutaneous leishmaniasis, to assess the efficiency of vector control interventions and perhaps to assess the risk of contracting the disease. Leishmaniasis results from an infection by Leishmania parasites that are transmitted through the bites of infected sand flies. This disease affects millions of people worldwide. Zoonotic cutaneous leishmaniasis is widespread in Central Tunisia and constitutes an actual public health problem. Leishmania major, the etiological agent, is transmitted by the sand fly vector Phlebotomus papatasi. Saliva of sand flies contains several pharmacologically active components that play a key role in the acquisition of the blood meal and the establishment of the parasites, thus enhancing the infection. Some of these molecules are able to elicit the production of specific antibodies, which can be used as markers of exposure to the vector’s bite. Herein, using a large cohort of individuals, we have validated the use of P. papatasi recombinant salivary protein PpSP32 (rPpSP32) as an alternative method to standard entomological studies for testing exposure to the bite of this sand fly in humans. rPpSP32 represents a promising epidemiological tool to monitor the spatial distribution of P. papatasi, direct control measures against zoonotic cutaneous leishmaniasis, evaluate the efficiency of vector control interventions and potentially assess the risk of contracting the disease.
- 14 September 2015
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 9 (9) , e0003991
Open AccessValidation of Recombinant Salivary Protein PpSP32 as a Suitable Marker of Human Exposure to Phlebotomus papatasi, the Vector of Leishmania major in Tunisia
During a blood meal, female sand flies, vectors of Leishmania parasites, inject saliva into the host skin. Sand fly saliva is composed of a large variety of components that exert different pharmacological activities facilitating the acquisition of blood by the insect. Importantly, proteins present in saliva are able to elicit the production of specific anti-saliva antibodies, which can be used as markers for exposure to vector bites. Serological tests using total sand fly salivary gland extracts are challenging due to the difficulty of obtaining reproducible salivary gland preparations. Previously, we demonstrated that PpSP32 is the immunodominant salivary antigen in humans exposed to Phlebotomus papatasi bites and established that humans exposed to P. perniciosus bites do not recognize it. Herein, we have validated, in a large cohort of 522 individuals, the use of the Phlebotomus papatasi recombinant salivary protein PpSP32 (rPpSP32) as an alternative method for testing exposure to the bite of this sand fly. We also demonstrated that screening for total anti-rPpSP32 IgG antibodies is sufficient, being comparable in efficacy to the screening for IgG2, IgG4 and IgE antibodies against rPpSP32. Additionally, sera obtained from dogs immunized with saliva of P. perniciosus, a sympatric and widely distributed sand fly in Tunisia, did not recognize rPpSP32 demonstrating its suitability as a marker of exposure to P. papatasi saliva. Our data indicate that rPpSP32 constitutes a useful epidemiological tool to monitor the spatial distribution of P. papatasi in a particular region, to direct control measures against zoonotic cutaneous leishmaniasis, to assess the efficiency of vector control interventions and perhaps to assess the risk of contracting the disease. Leishmaniasis results from an infection by Leishmania parasites that are transmitted through the bites of infected sand flies. This disease affects millions of people worldwide. Zoonotic cutaneous leishmaniasis is widespread in Central Tunisia and constitutes an actual public health problem. Leishmania major, the etiological agent, is transmitted by the sand fly vector Phlebotomus papatasi. Saliva of sand flies contains several pharmacologically active components that play a key role in the acquisition of the blood meal and the establishment of the parasites, thus enhancing the infection. Some of these molecules are able to elicit the production of specific antibodies, which can be used as markers of exposure to the vector’s bite. Herein, using a large cohort of individuals, we have validated the use of P. papatasi recombinant salivary protein PpSP32 (rPpSP32) as an alternative method to standard entomological studies for testing exposure to the bite of this sand fly in humans. rPpSP32 represents a promising epidemiological tool to monitor the spatial distribution of P. papatasi, direct control measures against zoonotic cutaneous leishmaniasis, evaluate the efficiency of vector control interventions and potentially assess the risk of contracting the disease.
- 3 July 2015
- Published by Wiley in International Journal of Dermatology
- Vol. 54 (8) , e319-e321
FOXP3transcription is enhanced in lesional and perilesional skin of patients with focalAlopecia areata
- 3 July 2015
- Published by Wiley in International Journal of Dermatology
- Vol. 54 (8) , e319-e321
FOXP3transcription is enhanced in lesional and perilesional skin of patients with focalAlopecia areata
- 1 December 2014
- Published by Elsevier in Joint Bone Spine
- Vol. 81 (6) , 550-551
The level of interleukin-17 in serum is linked to synovial hypervascularisation in rheumatoid arthritis
- 1 December 2014
- Published by Elsevier in Joint Bone Spine
- Vol. 81 (6) , 550-551
The level of interleukin-17 in serum is linked to synovial hypervascularisation in rheumatoid arthritis
- 3 November 2014
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 12 (5) , 648-649
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
- 3 November 2014
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 12 (5) , 648-649
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
- 1 May 2013
- Vol. 91 (5) , 337-41
[Does multiple myeloma response to induction therapy depend on plasma cell IL6 receptor gene expression?].
Interleukine 6 (IL-6) is the most important cytokine involved in malignant plasma cells growth and survival. To analyse bone marrow plasma cells IL6 receptor gene expression in both multiple myeloma patients at diagnosis and healthy bone marrow donors. Clinical and biological patients' features and responses to Dexamethasone-Thalidomide induction therapy were gathered. 47 patients and 16 case controls were analyzed: Bone marrow plasma cells were isolated; and IL6 receptor gene expression was quantified using Taqman quantitative PCr technology and 2-ΔCT formula. Quantitative and qualitative IL6 receptor gene expression were negatively correlated with the degree of response to therapy (p= 0.02). In this study, plasma cells IL6 receptor gene expression seems to be decisive in predicting the response to treatment. Understanding the mechanisms involved in plasma cells IL6 receptor gene expression may offer a better appreciation of the physiopathologic and anti-oncogenic ways of drug resistance in multiple myeloma and consequently the discovery of new specific drugs.
- 1 May 2013
- Vol. 91 (5) , 337-41
[Does multiple myeloma response to induction therapy depend on plasma cell IL6 receptor gene expression?].
Interleukine 6 (IL-6) is the most important cytokine involved in malignant plasma cells growth and survival. To analyse bone marrow plasma cells IL6 receptor gene expression in both multiple myeloma patients at diagnosis and healthy bone marrow donors. Clinical and biological patients' features and responses to Dexamethasone-Thalidomide induction therapy were gathered. 47 patients and 16 case controls were analyzed: Bone marrow plasma cells were isolated; and IL6 receptor gene expression was quantified using Taqman quantitative PCr technology and 2-ΔCT formula. Quantitative and qualitative IL6 receptor gene expression were negatively correlated with the degree of response to therapy (p= 0.02). In this study, plasma cells IL6 receptor gene expression seems to be decisive in predicting the response to treatment. Understanding the mechanisms involved in plasma cells IL6 receptor gene expression may offer a better appreciation of the physiopathologic and anti-oncogenic ways of drug resistance in multiple myeloma and consequently the discovery of new specific drugs.
- Open Access
- 29 November 2012
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 6 (11) , e1911
Salivary Antigen SP32 Is the Immunodominant Target of the Antibody Response to Phlebotomus papatasi Bites in Humans
Zoonotic cutaneous leishmaniasis (ZCL) due to Leishmania major is highly prevalent in Tunisia and is transmitted by a hematophagous vector Phlebotomus papatasi (P. papatasi). While probing for a blood meal, the sand fly injects saliva into the host's skin, which contains a variety of compounds that are highly immunogenic. We recently showed that the presence of anti-saliva antibodies was associated with an enhanced risk for leishmaniasis and identified the immunodominant salivary protein of Phlebotomus papatasi as a protein of approximately 30 kDa. We cloned and expressed in mammalian cells two salivary proteins PpSP30 and PpSP32 with predicted molecular weights close to 30 kDa from the Tunisian strain of P. papatasi. The two recombinant salivary proteins were purified by two-step HPLC (High-Performance Liquid Chromatography) and tested if these proteins correspond to the immunodominant antigen of 30 kDa previously shown to be recognized by human sera from endemic areas for ZCL and exposed naturally to P. papatasi bites. While recombinant PpSP30 (rPpSP30) was poorly recognized by human sera from endemic areas for ZCL, rPpSP32 was strongly recognized by the tested sera. The binding of human IgG antibodies to native PpSP32 was inhibited by the addition of rPpSP32. Consistently, experiments in mice showed that PpSP32 induced the highest levels of antibodies compared to other P. papatasi salivary molecules while PpSP30 did not induce any detectable levels of antibodies. Our findings demonstrate that PpSP32 is the immunodominant target of the antibody response to P. papatasi saliva. They also indicate that the recombinant form of PpSP32 is similar to the native one and represents a good candidate for large scale testing of human exposure to P. papatasi bites and perhaps for assessing the risk of contracting the disease. Leishmania is transmitted by female sand flies and deposited during a blood meal together with saliva. Saliva contains a vast repertoire of pharmacologically active molecules that facilitate the acquisition of the blood meal and contribute to the establishment of the infection. These molecules can induce the production of anti-saliva antibodies, which can be used as markers of exposure to the vector bite. Epidemiological studies using sand fly salivary gland extract as antigens are hampered by the difficulty in obtaining large amounts of salivary glands. In the present study, we have investigated the use of recombinant salivary proteins from the Tunisian strain of Phlebotomus papatasi, the main vector of zoonotic cutaneous leishmaniasis (ZCL) in Tunisia, as an alternative method for screening of exposure to the sand fly bites. We primarily identified PpSP32 as the immunodominant protein and described the low level of polymorphisms in the amino acid sequence of the target protein. Further, we tested the suitability of using the recombinant form of this protein to estimate positive anti-saliva antibodies in serum samples of individuals from an endemic area for ZCL. Our findings indicate that this protein represents a promising epidemiological tool that can aid in implementing control measures against leishmaniasis.
- 29 November 2012
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 6 (11) , e1911
Open AccessSalivary Antigen SP32 Is the Immunodominant Target of the Antibody Response to Phlebotomus papatasi Bites in Humans
Zoonotic cutaneous leishmaniasis (ZCL) due to Leishmania major is highly prevalent in Tunisia and is transmitted by a hematophagous vector Phlebotomus papatasi (P. papatasi). While probing for a blood meal, the sand fly injects saliva into the host's skin, which contains a variety of compounds that are highly immunogenic. We recently showed that the presence of anti-saliva antibodies was associated with an enhanced risk for leishmaniasis and identified the immunodominant salivary protein of Phlebotomus papatasi as a protein of approximately 30 kDa. We cloned and expressed in mammalian cells two salivary proteins PpSP30 and PpSP32 with predicted molecular weights close to 30 kDa from the Tunisian strain of P. papatasi. The two recombinant salivary proteins were purified by two-step HPLC (High-Performance Liquid Chromatography) and tested if these proteins correspond to the immunodominant antigen of 30 kDa previously shown to be recognized by human sera from endemic areas for ZCL and exposed naturally to P. papatasi bites. While recombinant PpSP30 (rPpSP30) was poorly recognized by human sera from endemic areas for ZCL, rPpSP32 was strongly recognized by the tested sera. The binding of human IgG antibodies to native PpSP32 was inhibited by the addition of rPpSP32. Consistently, experiments in mice showed that PpSP32 induced the highest levels of antibodies compared to other P. papatasi salivary molecules while PpSP30 did not induce any detectable levels of antibodies. Our findings demonstrate that PpSP32 is the immunodominant target of the antibody response to P. papatasi saliva. They also indicate that the recombinant form of PpSP32 is similar to the native one and represents a good candidate for large scale testing of human exposure to P. papatasi bites and perhaps for assessing the risk of contracting the disease. Leishmania is transmitted by female sand flies and deposited during a blood meal together with saliva. Saliva contains a vast repertoire of pharmacologically active molecules that facilitate the acquisition of the blood meal and contribute to the establishment of the infection. These molecules can induce the production of anti-saliva antibodies, which can be used as markers of exposure to the vector bite. Epidemiological studies using sand fly salivary gland extract as antigens are hampered by the difficulty in obtaining large amounts of salivary glands. In the present study, we have investigated the use of recombinant salivary proteins from the Tunisian strain of Phlebotomus papatasi, the main vector of zoonotic cutaneous leishmaniasis (ZCL) in Tunisia, as an alternative method for screening of exposure to the sand fly bites. We primarily identified PpSP32 as the immunodominant protein and described the low level of polymorphisms in the amino acid sequence of the target protein. Further, we tested the suitability of using the recombinant form of this protein to estimate positive anti-saliva antibodies in serum samples of individuals from an endemic area for ZCL. Our findings indicate that this protein represents a promising epidemiological tool that can aid in implementing control measures against leishmaniasis.
- 12 October 2011
- Published by Springer Nature
- p. 25-42
Immunological Aspects of Systemic Vasculitis
Primary vasculitis are commonly multifactorial disorders involving environmental, genetic and immunological factors. Several immune-based effector mechanisms are implicated in the vascular wall damage. These effector mechanisms commonly imply auto-antibodies or immune complexes - mediated cytotoxicity but the contribution of a T-cell mediated immune response has also been described, particularly in large vascular vasculitis. Despite advances in understanding the pathophysiological mechanisms of vasculitis, the triggering events initiating the disease remain largely undefined in most cases. This review highlights the recent advances in the etiopathogenesis of primary vasculitis. A better understanding of the immunological aspects of these disorders may provide insight into the development of novel therapeutical strategies.
- 12 October 2011
- Published by Springer Nature
- p. 25-42
Immunological Aspects of Systemic Vasculitis
Primary vasculitis are commonly multifactorial disorders involving environmental, genetic and immunological factors. Several immune-based effector mechanisms are implicated in the vascular wall damage. These effector mechanisms commonly imply auto-antibodies or immune complexes - mediated cytotoxicity but the contribution of a T-cell mediated immune response has also been described, particularly in large vascular vasculitis. Despite advances in understanding the pathophysiological mechanisms of vasculitis, the triggering events initiating the disease remain largely undefined in most cases. This review highlights the recent advances in the etiopathogenesis of primary vasculitis. A better understanding of the immunological aspects of these disorders may provide insight into the development of novel therapeutical strategies.